Chad Pecot, MD
@chadpecot.bsky.social
Cancer Killer | Engineering RNA medicines to End Cancer | Potentially sarcastic | Honey-badger
Pinned
Chad Pecot, MD
@chadpecot.bsky.social
· Jun 26
Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor.
We address two major challenges with RNAi therapeutics in cancer:
1) Delivery, delivery, delivery
2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
We address two major challenges with RNAi therapeutics in cancer:
1) Delivery, delivery, delivery
2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor.
We address two major challenges with RNAi therapeutics in cancer:
1) Delivery, delivery, delivery
2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
We address two major challenges with RNAi therapeutics in cancer:
1) Delivery, delivery, delivery
2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
June 26, 2025 at 5:08 PM
Now in @Cancer_Cell our group reports the development of a first-in-class EGFR-directed KRAS G12V selective inhibitor.
We address two major challenges with RNAi therapeutics in cancer:
1) Delivery, delivery, delivery
2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
We address two major challenges with RNAi therapeutics in cancer:
1) Delivery, delivery, delivery
2) Achieving mutant selectivity
www.cell.com/cancer-cell/...
(1/11)
Reposted by Chad Pecot, MD
Online Now: A first-in-class EGFR-directed KRAS G12V selective inhibitor
A first-in-class EGFR-directed KRAS G12V selective inhibitor
Despite KRAS G12V being a common mutation in cancer, no direct inhibitors currently exist. Stanland et al. demonstrate that an EGFR-directed RNAi platform, EFTX-G12V, selectively targets KRAS G12V while sparing wild-type KRAS. EFTX-G12V shows significant anti-tumor effects and provides insights into mutant-selective KRAS targeting and improved therapeutic activity.
dlvr.it
June 19, 2025 at 6:51 PM
Online Now: A first-in-class EGFR-directed KRAS G12V selective inhibitor